iTeos Therapeutics Collaborates with Merck to Evaluate EOS100850 + Keytruda (pembrolizumab) for Solid Tumors

 iTeos Therapeutics Collaborates with Merck to Evaluate EOS100850 + Keytruda (pembrolizumab) for Solid Tumors

iTeos Therapeutics Collaborates with Merck to Evaluate EOS100850 + Keytruda (pembrolizumab) for Solid Tumors

Shots:

  • The companies collaborate to initiate P-I/II study assessing the combination of iTeos’ EOS100850 and Merck’s Keytruda (pembrolizumab) for patients with solid tumors. The companies plan the onset of the study in H1’20
  • The focus of the study is to determine the safety and tolerability of the combination regimen in solid tumors
  • EOS100850 is a non-brain penetrant A2A receptor antagonist that holds potency in the presence of elevated adenosine concentrations, measured in the tumor microenvironment and is being evaluated in P-I/Ib as monothx.

Click here to­ read full press release/ article | Ref: iTeos Therapeutics | Image: HBM Partners

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post